


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT

INSILICO MEDICINE COMPLETED FIRST PATIENT ENROLLMENT AND DOSING IN PHASE III (GENESIS-IPF-3) CLINICAL TRIAL OF RENTOSERTIB, ITS LEADING AI-DRIVEN INNOVATIVE DRUG CANDIDATE FOR IPF

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**InSilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, Rentosertib (also known as ISM001-055/INS018_055), the Company’s leading AI-driven innovative drug candidate in our pipeline, has completed first patient enrollment and dosing in its Phase III (GENESIS-IPF-3) clinical trial at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient for the trial on the same day.

GENESIS-IPF-3 is a Phase III clinical trial (NCT07687459, CTR20262475) for evaluating Rentosertib in patients with idiopathic pulmonary fibrosis (IPF). The 52-week, prospective, randomized, multi-center, double-blind, placebo-controlled, parallel-group Phase III study in patients with IPF is expected to enroll a total of 320 participants across 47 clinical centers in China. The primary endpoint is the annual rate of decline in forced vital capacity (FVC) over 52 weeks. The key secondary endpoint is time to first occurrence of any disease progression event. The trial is intended to assess whether Rentosertib can provide clinically meaningful benefit in a larger patient population and over a longer treatment period than the Phase IIa study.

This Phase III clinical study is led by Professor Xu Zuojun of Peking Union Medical College Hospital, alongside Academician Zhong Nanshan of the Chinese Academy of Engineering, a renowned expert in the field of respiratory medicine, and Dr. Chen Chang, Director of Shanghai Pulmonary Hospital, who serves as Co-Leading Principal Investigators.

About Rentosertib (ISM001-055)

Rentosertib is a potentially first-in-class small molecule inhibitor targeting TNIK and discovered and developed utilizing the Company's proprietary generative AI platform, Pharma.AI. In IPF, the activation of TNIK drives pathological fibrosis in the lungs, contributing to the progressive decline in lung function. By inhibiting TNIK, Rentosertib aims to halt or reverse fibrotic processes, offering a disease-modifying treatment for patients with IPF.

In the GENESIS-IPF Phase IIa clinical trial, Rentosertib demonstrated a favorable safety profile alongside dose-dependent efficacy trends, marking an industry-first proof of concept for AI-driven drug discovery. The findings were published in *Nature Medicine* in June 2025.

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a chronic, scarring lung disease characterized by a progressive and irreversible decline in lung function. Affecting approximately 5 million people worldwide, IPF carries a poor prognosis, with a median survival of 3 to 4 years. Current approved treatments, including antifibrotic drugs, can slow disease progression but do not stop or reverse it, leaving a significant unmet need for more effective, disease-modifying therapies.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The Company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico Medicine is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico Medicine extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, September 10, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as a non-executive director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.